title: Continent urinary reconstruction in rhabdomyosarcoma: a new approach.
abstract: OBJECTIVE
  The authors present here 5 cases of continent urinary diversion in rhabdomyosarcoma applying a recently described technique for the Mitrofanoff Principle devised by the authors.
  
  
  METHODS
  Two previously irradiated rhabdomyosarcoma patients presenting with residual bladder disease and massive sensitive urinary urgency underwent a transverse colonic reservoir with catheterizable stoma. Two other patients presenting with a Bricker conduit underwent conversion into an ileal reservoir. One patient underwent reconstruction after a cystectomy.
  
  
  RESULTS
  All patients were continent and able to perform continent intermittent catheterization.
  
  
  CONCLUSIONS
  The technique proved to be feasible for this group of patients. The authors believe that because of its simplicity, it should be an option of continent urinary diversion when the Mitrofanoff Principle is considered.
authors.affiliation: Division of Pediatric Urology, Department of Surgery/Pediatrics, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: Ricardo G
authors.initials: RG
authors.lastname: Freitas
authors.forename: Yuri T Dantas A
authors.initials: YT
authors.lastname: Nobre
authors.forename: Antonio
authors.initials: A
authors.lastname: Macedo
authors.forename: Guilherme T S
authors.initials: GT
authors.lastname: Demarchi
authors.forename: Valdemar
authors.initials: V
authors.lastname: Ortiz
authors.forename: Miguel
authors.initials: M
authors.lastname: Srougi
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D044684:Colon, Transverse / Q000601:surgery; D039021:Colonic Pouches; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D015653:Cystectomy; D003609:Dactinomycin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D018714:Radiotherapy, Adjuvant; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D018232:Rhabdomyosarcoma, Alveolar / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D018805:Sepsis / Q000209:etiology; D014523:Urethral Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D014546:Urinary Catheterization; D014547:Urinary Diversion / Q000379:methods*; D014552:Urinary Tract Infections / Q000209:etiology; D014565:Urogenital Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D014625:Vaginal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide